Associate Professor - Department of Neurological Sciences
Director - Huntington’s Disease Center
||Clinic Practice Location:|
4242 Farnam Street, Suite 650
988440 Nebraska Medical Center
- University of Nebraska Medical Center, MD (2003-2007)
- University of Nebraska Medical Center, Internal Medicine Internship (2007-2008)
- University of California-Davis Medical Center, Neurology Residency (2008-2011)
- Philadelphia VA Medical Center and University of Pennsylvania, Movement Disorders Fellowship (2011-2013)
University of Nebraska Medical Center
Huntington’s Disease, Chorea, Parkinson Disease, Gait Abnormalities, Ataxia, Dystonia, Botulinum Toxin Injections, Spasticity, Deep Brain Stimulation
Dr. Amy Hellman is an Associate Professor in the Department of Neurological Sciences at the University of Nebraska Medical Center. She attended the University of Nebraska Medical Center where she received her medical degree and completed her internship in Internal Medicine. She then completed Neurology residency training at UC Davis Medical Center, where she was appointed Neurology Chief Resident from 2010-2011. Dr. Hellman held a joint appointment at the Philadelphia VA Medical Center and the University of Pennsylvania where she completed her fellowship in Movement Disorders. She joined the UNMC faculty in August 2013. Dr. Hellman is board certified by the American Board of Psychiatry and Neurology. She directs the HDSA Center of Excellence at Nebraska Medicine and the UNMC Neurology Residency Program. She is a member of the American Academy of Neurology, the Movement Disorder Society and the Huntington Study Group. Dr. Hellman evaluates patients with movement disorders including Parkinson Disease, Huntington’s Disease, Chorea, Dystonia, Ataxia, Gait Abnormalities, and Spasticity. She also performs Botulinum Toxin injections and evaluates patients for Deep Brain Stimulation. Her research interests include Parkinson Disease and Huntington Disease.
Dr. Hellman's Active Clinical Research:
Optimizing Gait in PD
ENROLL HD: A Prospective Registry Study in a Global Huntington Disease Cohort
Hellman A, Shah S, Morley J, Duda J: Continuous non-invasive monitoring to detect covert autonomic dysfunction in Parkinson's disease. Parkinsonism and Related Disorders. July 2015.
Hellman A, Torres-Russotto D: Botulinum toxin in the management of blepharospasm: current evidence and recent developments. Therapeutic Advances in Neurological Disorders. March 2015.
Bhatti D, Thompson R, Hellman A, Penke C, Bertoni JM, Torres-Russotto D: Smartphone apps provide a simple, accurate bedside screening tool for Orthostatic Tremor. Movement Disorders Clinical Practice. October 2017.
Marmelat V, Reynolds N, Hellman A: Gait dynamics in Parkinson’s disease: Short gait trials ‘stitched’ together provide different fractal fluctuations compared to longer trials. Frontiers in Physiology, section Fractals Physiology. July 2018.
Bhatti D, Thompson R, Xia Y, Hellman A, Schmaderer L, Suing K, McKune J, Penke C, Iske R, Roeder BJ, Siu KC, Bertoni JM, Torres-Russotto D: Comprehensive, blinded assessment of balance in orthostatic tremor. Parkinsonism and Related Disorders. February 2018.
Kendrick LM, Hudgell D, Hellman A, Weaver MS: Attending to Total Pain in Juvenile Huntington Disease: A Case Report Informed by Narrative Review of the Literature. Journal of Palliative Care. April 2019.
Thompson R, Bhatti DE, Hellman A, Doss SJ, Malgireddy K, Shou J, Srikanth-Mysore C, Bendi S, Bertoni JM, Torres-Russotto D: Ataxia Prevalence in Primary Orthostatic Tremor. Tremor and Other Hyperkinetic Movements. December 2020.
Marmelat V, Duncan A, Meltz S, Meidinger RL, Hellman A. Fractal Auditory Stimulation has a greater benefit for people with Parkinson’s Disease showing more random gait pattern. Gait & Posture. July 2020.